<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765400</url>
  </required_header>
  <id_info>
    <org_study_id>574-11-FB</org_study_id>
    <nct_id>NCT01765400</nct_id>
  </id_info>
  <brief_title>Platelet Inhibition in Patients With Systolic Heart Failure</brief_title>
  <official_title>Platelet Reactivity With Clopidogrel Versus Prasugrel in Patients With Systolic Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to determine if patients with systolic heart failure treated with&#xD;
      prasugrel achieve greater platelet inhibition compared to those treated with clopidogrel.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thienopyridine antiplatelet agents are an important component of therapy for management of&#xD;
      acute coronary syndrome (ACS). Dual antiplatelet therapy with a thienopyridine, most commonly&#xD;
      clopidogrel, and aspirin is widely used in the management of ACS to prevent major adverse&#xD;
      cardiovascular events. Despite the benefits of this regimen, many patients continue to&#xD;
      develop atherothrombotic events while on this regimen. Various reasons including&#xD;
      inter-patient variability, delayed onset of action, and the obtainable antiplatelet activity&#xD;
      of clopidogrel have been described as potential causes of the limited efficacy in preventing&#xD;
      recurrent events. The Trial to assess improvement in therapeutic outcomes by optimizing&#xD;
      platelet inhibition with prasugrel-thrombolysis in myocardial infarction (TRITON-TIMI 38)&#xD;
      showed that patients with moderate-to-high-risk ACS scheduled for percutaneous coronary&#xD;
      intervention (PCI) treated with prasugrel had decreased cardiovascular events compared to&#xD;
      clopidogrel.&#xD;
&#xD;
      Clopidogrel is a prodrug that requires two hepatic conversion steps by the cytochrome&#xD;
      (CYP)P450 enzyme system. The need for CYP450 involvement is known to contribute to the&#xD;
      variable response of platelet inhibition demonstrated with clopidogrel. Although prasugrel is&#xD;
      also a thienopyridine, it only requires hepatic CYP450 enzymes for one conversion step, and&#xD;
      is converted to the active metabolite more efficiently. Therefore, prasugrel provides&#xD;
      significantly more potent platelet inhibition compared to clopidogrel.&#xD;
&#xD;
      Patients with advanced systolic heart failure commonly have elevated hepatic venous pressures&#xD;
      that can cause hepatic congestion and hypoperfusion resulting in impaired hepatic function.&#xD;
      The elevated hepatic venous pressure predominantly affects the hepatic centrilobular cells&#xD;
      which contain the highest concentration of cytochrome P-450 (CYP450) enzyme system. Hence&#xD;
      patients with advanced heart failure may convert less clopidogrel to the active metabolite&#xD;
      and subsequently produce less platelet inhibition compared to prasugrel.&#xD;
&#xD;
      Since prasugrel only requires the CYP450 system for one conversion step, the impact of&#xD;
      hepatic congestion should be limited for heart failure patients treated with prasugrel. The&#xD;
      phase 3, multi-center TRITON-TIMI 38 trial comparing clopidogrel and prasugrel showed that in&#xD;
      an unselected patient population presenting with ACS, prasugrel achieved greater&#xD;
      cardiovascular event reduction that was attributed to more robust platelet inhibition. Hence,&#xD;
      we designed this trial to prospectively test the hypothesis that systolic heart failure&#xD;
      patients with increased circulating catecholamines and possible abnormal functioning of&#xD;
      CYP450 system treated with prasugrel will achieve greater platelet reactivity inhibition&#xD;
      compared to those treated with clopidogrel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2013</start_date>
  <completion_date type="Actual">December 28, 2015</completion_date>
  <primary_completion_date type="Actual">December 1, 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in platelet aggregation measured by the Accumetrics (VerifyNow P2Y12) assay between baseline and each antiplatelet medication</measure>
    <time_frame>Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in light transmission aggregometry (LTA)between baseline and each antiplatelet medication</measure>
    <time_frame>Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in platelet activation assay (VASP)between baseline and each antiplatelet medication</measure>
    <time_frame>Baseline, 2 weeks post clopidogrel, and 2 weeks post prasugrel</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Systolic Heart Failure</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 10 mg once daily for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 75 mg once daily for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel 10 mg daily x 2 weeks</intervention_name>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 mg daily x 2 weeks</intervention_name>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 19 to 74 years of age.&#xD;
&#xD;
          -  Patients with a left ventricular ejection fraction &lt;35% by echocardiogram, SPECT&#xD;
             myocardial perfusion study, cardiac MRI, cardiac computerized tomographic angiogram or&#xD;
             invasive left ventricular angiogram within the last 6 months.&#xD;
&#xD;
          -  Patients with NYHA Class III-IV heart failure at the time of enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent hospitalization within 30 days&#xD;
&#xD;
          -  Patients expected to undergo major surgery or PCI in the next 30 days&#xD;
&#xD;
          -  Patients taking clopidogrel, prasugrel, ticagrelor, ticlopidine, or cilostazol&#xD;
&#xD;
          -  Patients listed for heart transplantation or having left ventricular assist device&#xD;
             placement&#xD;
&#xD;
          -  Patients with known allergy to either medication&#xD;
&#xD;
          -  Patients with prior history of stroke or transient ischemic attack&#xD;
&#xD;
          -  Patients with known intracranial neoplasm, aneurysm, or arteriovenous malformation&#xD;
&#xD;
          -  Patients with a history of bleeding requiring hospitalization for treatment&#xD;
&#xD;
          -  Patients taking oral anticoagulants&#xD;
&#xD;
          -  Patients with body weight &lt;60 kg&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  Patients with hemoglobin &lt;10 mg/dl or platelet count &lt;100,000/ul at baseline&#xD;
&#xD;
          -  Patients with known clotting or platelet disorders&#xD;
&#xD;
          -  Patients with a baseline INR &gt; 1.4&#xD;
&#xD;
          -  Patients with liver function tests (AST or ALT) &gt; 2 times normal&#xD;
&#xD;
          -  Patients with a suspected change in their use of aspirin during the study (starting,&#xD;
             stopping, or changing dose of aspirin)&#xD;
&#xD;
          -  Patients unwilling to consent to CYP2C19 genetic testing.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul P Dobesh, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebaska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>December 12, 2012</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>September 28, 2017</last_update_submitted>
  <last_update_submitted_qc>September 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Nebraska</investigator_affiliation>
    <investigator_full_name>Paul Dobesh, PharmD</investigator_full_name>
    <investigator_title>Associate Professor of Pharmacy Practice</investigator_title>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Antiplatelet therapy</keyword>
  <keyword>Platelet aggregation</keyword>
  <keyword>Clopidogrel</keyword>
  <keyword>Prasugrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Systolic</mesh_term>
    <mesh_term>Systolic Murmurs</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 16, 2018</submitted>
    <returned>February 12, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

